1 completed, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow AT-511: new trials by email Literature Review of AT-511 trials Research Report on AT-511
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19 Bemnifosbuvir (BEM), Placebo - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19 | Phase 3 | Completed | Atea Pharmaceuticals, Inc. | 2285 | 2022-11-25 | 2025-06-13 |
| Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19 RO7496998, Placebo - COVID-19 | Phase 3 | Terminated | Hoffmann-La Roche | 216 | 2021-04-28 | 2024-01-05 |
COVID-19 (2)
Atea Pharmaceuticals, Inc. (1) · Hoffmann-La Roche (1)
Argentina (2) · Brazil (2) · Germany (2) · Japan (2) · Mexico (2) · Romania (2) · Turkey (Türkiye) (2) · Belgium (1) · Canada (1) · Denmark (1) · India (1) · Latvia (1) · Netherlands (1) · Pakistan (1) · Philippines (1)